首页> Cancer discovery> NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.

导出 OA

翻译打印收藏纠错

第一作者： Alexander,Drilon

第一单位： Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

作者： Alexander,Drilon ^[1] ; Joshua C,Horan ^[2] ; Anupong,Tangpeerachaikul ^[2] ; Benjamin,Besse ^[3] ; Sai-Hong Ignatius,Ou ^[4] ; Shirish M,Gadgeel ^[5] ; D Ross,Camidge ^[6] ; Anthonie J,van der Wekken ^[7] ; Linh,Nguyen-Phuong ^[8] ; Adam,Acker ^[8] ; Clare,Keddy ^[9] ; Katelyn S,Nicholson ^[9] ; Satoshi,Yoda ^[10] ; Scot,Mente ^[2] ; Yuting,Sun ^[2] ; John R,Soglia ^[2] ; Nancy E,Kohl ^[11] ; James R,Porter ^[2] ; Matthew D,Shair ^[2] ; Viola,Zhu ^[2] ; Monika A,Davare ^[9] ; Aaron N,Hata ^[10] ; Henry E,Pelish ^[2] ; Jessica J,Lin ^[10]

作者单位： Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. ^[1] Nuvalent, Inc., Cambridge, Massachusetts. ^[2] Institut Gustave Roussy, Villejuif, France. ^[3] University of California Irvine Medical Center, Orange, California. ^[4] Henry Ford Cancer Institute, Detroit, Michigan. ^[5] University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado. ^[6] University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. ^[7] Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. ^[8] Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.;Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon. ^[9] Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.;Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. ^[10] Nuvalent, Inc., Cambridge, Massachusetts.;Kohl Consulting, Wellesley, Massachusetts. ^[11]